drugset

drugset / Trial / NCT05488405

Mesalazine Oral Suspension in Active Eosinophilic Esophagitis

NCT05488405 ↗

Phase 2 Completed 5 enrolled Dr. Falk Pharma GmbH

NaSingle-groupOpen-labelTreatment

Summary

Pilot study to assess a mesalazine oral suspension in active eosinophilic esophagitis

Timeline

Start: 2023-02-09
Primary completion: 2023-06-30
Completion: 2023-07-20

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Mesalamine	Small molecule	—	Oral

Indications